Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...

Whether you're a tech junkie or a casual user who's seen every era of computing, you likely have plenty of old tech ephemera in your home. Maybe it's a desk drawer or closet (or even a tote) filled ...